Literature DB >> 20955720

Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs.

H J Otton1, A Lawson McLean, M A Pannozzo, C H Davies, D J A Wyllie.   

Abstract

Clinically, amantadine and memantine are drugs whose therapeutic utility is linked to their ability to block N-methyl-D-aspartate receptors (NMDARs) in a voltage-dependent manner. Nevertheless many studies that have characterized the pharmacological actions of amantadine and memantine have done so in the absence of physiological levels of Mg(2+) ions. This study quantifies the extent to which Mg(2+) alters the potency of the block produced by both amantadine and memantine at human recombinant GluN1/GluN2A NMDARs. Human recombinant GluN1/GluN2A NMDARs were expressed in Xenopus laevis oocytes and two-electrode voltage-clamp recordings were made at -80, -60 and -40 mV to quantify amantadine and memantine block in the absence and presence of Mg(2+). Amantadine and memantine blocked human GluN1/GluN2A NMDARs in a voltage-dependent manner with IC(50) values (at -80 mV) of 49 ± 6 μM (n = 7) and 1.0 ± 0.3 μM (n = 7), respectively. In the presence of Mg(2+) (1mM) the equivalent IC(50) values were 165 ± 10 μM (n=6) and 6.6 ± 0.3 μM (n = 5). Similarly in the presence of amantadine or memantine the potency of Mg(2+) in blocking GluN1/GluN2A NMDARs was reduced. The decrease in the potencies of both amantadine and memantine in the presence of physiological concentrations of Mg(2+) indicates that other targets (e.g. α7-nicotinic acetylcholine receptors and 5-HT(3) receptors) in addition to NMDARs may well be sites of the therapeutic action of these channel blockers.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955720     DOI: 10.1016/j.neuropharm.2010.10.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  11 in total

1.  Effects of Mg2+ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.

Authors:  Nathan G Glasgow; Madeleine R Wilcox; Jon W Johnson
Journal:  Neuropharmacology       Date:  2018-05-12       Impact factor: 5.250

2.  The Role of GluN2C-Containing NMDA Receptors in Ketamine's Psychotogenic Action and in Schizophrenia Models.

Authors:  Elizaveta Khlestova; Jon W Johnson; John H Krystal; John Lisman
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

Review 3.  Recent insights into the mode of action of memantine and ketamine.

Authors:  Jon W Johnson; Nathan G Glasgow; Nadezhda V Povysheva
Journal:  Curr Opin Pharmacol       Date:  2014-12-02       Impact factor: 5.547

4.  Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.

Authors:  Andreea L Turcu; Júlia Companys-Alemany; Matthew B Phillips; Dhilon S Patel; Christian Griñán-Ferré; M Isabel Loza; José M Brea; Belén Pérez; David Soto; Francesc X Sureda; Maria G Kurnikova; Jon W Johnson; Mercè Pallàs; Santiago Vázquez
Journal:  Eur J Med Chem       Date:  2022-04-08       Impact factor: 7.088

5.  Key binding interactions for memantine in the NMDA receptor.

Authors:  Walrati Limapichat; Wesley Y Yu; Emma Branigan; Henry A Lester; Dennis A Dougherty
Journal:  ACS Chem Neurosci       Date:  2012-12-07       Impact factor: 4.418

6.  Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.

Authors:  S McKay; N H Griffiths; P A Butters; E B Thubron; G E Hardingham; D J A Wyllie
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

7.  The human NMDA receptor GluN2AN615K variant influences channel blocker potency.

Authors:  Katie F M Marwick; Paul A Skehel; Giles E Hardingham; David J A Wyllie
Journal:  Pharmacol Res Perspect       Date:  2019-06-20

8.  Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones.

Authors:  A R Wild; E Akyol; S L C Brothwell; P Kimkool; J N Skepper; A J Gibb; S Jones
Journal:  Neuropharmacology       Date:  2013-05-28       Impact factor: 5.250

Review 9.  Influence of GluN2 subunit identity on NMDA receptor function.

Authors:  D J A Wyllie; M R Livesey; G E Hardingham
Journal:  Neuropharmacology       Date:  2013-01-31       Impact factor: 5.250

10.  TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner.

Authors:  S Edman; S McKay; L J Macdonald; M Samadi; M R Livesey; G E Hardingham; D J A Wyllie
Journal:  Neuropharmacology       Date:  2012-05-01       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.